A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT06868381
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cardiac Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

Key Dates

Start date
Apr 1, 2026
Status verified
Feb 2026
Primary completion
Jul 1, 2028
Completion
Dec 1, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: baricitinib + steroid-sparing drug +/- glucocorticoid taper
    * Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication * Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol

Primary Outcome Measure

Proportion of patients with resolution of cardiac FDG uptake on PET-CT [ Time Frame: From baseline to end of treatment at 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94304-2210
Angie Aberia
[email protected]
650-723-8516
Matthew C Baker, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By research site
Stanford University· Palo Alto, CA

Related Studies